Discussions on the range of toxic Chinese herbal medicines and other correlated issuesZHOU Yue-hua, LU Jin-cai1926-1940
Analysis of monoclonal antibody drug registration in ChinaKAN Hong-jin, LIU Bo-ning, BAI Yu, LUO Jian-hui1941-1946
Roles of the components of product formulation of monoclonal antibodies and the points to consider for drug evaluationQIU Xiao, LUO Jian-hui1947-1954
Case introduction of PD-1 immune checkpoint inhibitors combined medication approved by FDAGAO Li-li, WANG Yu-zhu, YANG Jin-bo1955-1963
Considerations on research and evaluation of virus safety for recombinant biological productsWEI Wei, XU Long-chang, BAI Yu, LUO Jian-hui1964-1968
Analysis of repeated applications of approved biological productsLIU Zhi-lei, ZHANG Yan-yan, GAO En-ming1969-1974
Discussion on quality control strategy and case study of mesenchymal stem cells products from regulatory perspectiveYU Shan-shan, WEI Kai-kun1975-1981
Introduction to the ICH considerations on nonclinical studies of oncolytic virus products in conjugation with the practice of talimogene laherparepvecZHANG Min, GONG Xin-jiang, SHAO Xue, YAN Li-ping, YU Bing, YE Xuan, WANG Qing-li, WANG Hai-xue1982-1986
Latest related requirements on starting materials for synthetic drug substancesWANG Hong-liang, WANG Huan1987-1990